PALO
ALTO, Calif., Jan. 7, 2025
/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a
biopharmaceutical company committed to researching, developing and
commercializing transformative therapeutics to treat a broad
spectrum of retinal diseases, announced today that Victor Perlroth, M.D., Chief Executive Officer,
will present at the 43rd Annual J.P. Morgan Healthcare
Conference in San Francisco, CA on
Wednesday, January 15, 2025, at
3:00 p.m. Pacific Time.
A live webcast of the presentation will be available on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the event.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical
company committed to researching, developing, and commercializing
transformative therapeutics to treat a broad spectrum of retinal
diseases. We are focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Our ABC Platform™
uses molecular engineering to merge the fields of protein-based and
chemistry-based therapies and has been at the core of Kodiak's
discovery engine. We are developing a portfolio of three clinical
programs, two of which are late-stage today and derived from our
ABC Platform and one which is platform-independent and which we
believe can progress rapidly into pivotal studies.
Kodiak's lead investigational medicine, tarcocimab, is a novel
anti-VEGF antibody biopolymer conjugate under development for the
treatment of high prevalence retinal vascular diseases. Tarcocimab
is currently being studied in two Phase 3 clinical trials, GLOW2 in
patients with diabetic retinopathy and DAYBREAK in patients with
wet AMD. Both studies are actively enrolling patients.
KSI-501 is our second investigational medicine, a first-in-class
anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate
designed to inhibit both IL-6 mediated inflammation and
VEGF-mediated angiogenesis and vascular permeability. KSI-501 is
being developed for the treatment of high prevalence retinal
vascular diseases to address the unmet needs of extended durability
and targeting disease biology beyond VEGF for differentiated
efficacy. The Phase 3 DAYBREAK study of KSI-501 in wet AMD is
actively enrolling patients.
KSI-101, our third product candidate, is a novel anti-IL-6,
VEGF-trap bispecific protein. Kodiak is developing KSI-101 for the
treatment of retinal inflammatory diseases, as currently there are
no available intravitreal biologic therapies addressing the
spectrum of inflammatory conditions of the retina. The Phase
1b APEX study of KSI-101 is actively
enrolling patients, as a precursor to activating the Phase
2b/3 PEAK and PINNACLE studies in
patients with macular edema secondary to inflammation
("MESI").
Kodiak is advancing its platform technology to embed small
molecules and other active pharmaceutical ingredients ("APIs") into
Kodiak's proprietary biopolymer backbone to enable high
drug-antibody-ratio ("DAR") medicines. The diverse APIs are
designed to be released over time to achieve targeted,
multi-specific and tailored modulation of biological pathways. The
unique combination of high DAR and tailored therapeutic benefit
offers potential for broad application to multifactorial diseases
and builds directly from our Antibody Biopolymer Conjugate
technology and its 15 years of design, development and
manufacturing experience. We call this platform extension our
Antibody Biopolymer Conjugate Drug ("ABCD") Platform because we are
extending our platform capabilities to include the conjugation of
small molecule drugs and other APIs whereas historically, we
primarily conjugated biologics such as antibodies.
For more information, please
visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC ™, ABC Platform™, ABCD™
and the Kodiak logo are registered trademarks or trademarks
of Kodiak Sciences Inc. in various global
jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302343959.html
SOURCE Kodiak Sciences Inc.
